{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:42:25Z","timestamp":1784421745783,"version":"3.55.0"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"2","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,6]]},"abstract":"<jats:p>Twenty-five years ago, the FDA gave the first approval to an antibody\u2013drug conjugate (ADC), the CD33-targeting gemtuzumab ozogamicin for acute myeloid leukemia. As the drug faced setbacks and redemption\u2014it was withdrawn in 2010 following poor phase III trial results but reapproved in 2017 at a lower dose\u2014a surge of pharmaceutical interest in ADCs has yielded newly approved agents and new strategies for developing them.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nw2025-0117","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:28:15Z","timestamp":1767616095000},"page":"OF1-OF1","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer Throughlines: 25 Years after First Approval, ADCs Continue to Pick up Steam"],"prefix":"10.1158","volume":"16","member":"1086","published-online":{"date-parts":[[2025,12,31]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-NW2025-0117\/771451\/Cancer-Throughlines-25-Years-after-First-Approval","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/2\/OF1\/772106\/Cancer-Throughlines-25-Years-after-First-Approval","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/2\/OF1\/772106\/Cancer-Throughlines-25-Years-after-First-Approval","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:34:27Z","timestamp":1770651267000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/2\/OF1\/772106\/Cancer-Throughlines-25-Years-after-First-Approval"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12,31]]},"published-print":{"date-parts":[[2026,2,6]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nw2025-0117","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}